Starbucks Expands Coconut Water Beverages As It Focuses On Wellness
U.S. coffee chain Starbucks (SBUX) is expanding its test of coconut water beverages as it pushes further into the health and wellness space.The Seattle-based company says it plans to test its Coco Matcha and Coco Cold Brew drinks in more than 400 stores across the U.S., starting with New York City, Los Angeles, and Chicago. The drinks layer matcha foam or cold brew foam over coconut water and are marketed as a healthy beverage option for consumers. The drinks were first tested in New York City as a part of Starbucks’ “Starting Five” program that is exploring new ideas and seeking feedback from baristas and customers.The push into wellness comes as Starbucks targets younger consumers who want customized cold drinks and healthier options.It also comes as Starbucks tries to revive its slumping sales, particularly in its home market of America. The company has been in decline since the end of the Covid-19 pandemic. Starbucks is also undertaking a “Back to Starbucks” turnaround plan under new Chief Executive Officer (CEO) Brian Niccol, featuring cafe renovations and menu changes. As the strategy takes shape, Starbucks executives have said the company has seen increases in satisfaction levels among younger consumers in the Gen Z and Millennial demographics.SBUX stock has declined 3% this year to trade at $89.51 U.S. per share.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


